Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Alnylam Pharmaceuticals
(NQ:
ALNY
)
262.69
-24.32 (-8.47%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 30, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
3,762,559
Open
266.00
Bid (Size)
262.00 (15)
Ask (Size)
263.99 (1)
Prev. Close
287.01
Today's Range
256.91 - 273.24
52wk Range
141.97 - 287.55
Shares Outstanding
118,847,693
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Market Whales and Their Recent Bets on ALNY Options
August 30, 2024
Via
Benzinga
Alnylam Pharmaceuticals Stock Falls After Detailed Vutrisiran Data For A Condition With Stiff Heart Muscles
August 30, 2024
Alnylam Pharmaceuticals shares drop as detailed results from the HELIOS-B Phase 3 study of vutrisiran for ATTR-CM reveal mixed outcomes. Reductions in mortality and cardiovascular events were presented...
Via
Benzinga
Performance
YTD
+34.76%
+34.76%
1 Month
-2.20%
-2.20%
3 Month
+74.60%
+74.60%
6 Month
+75.08%
+75.08%
1 Year
+30.58%
+30.58%
More News
Read More
Alnylam Plummets, Reversing 50% Gain This Year, As Pfizer Rival Lags Expectations
August 30, 2024
Via
Investor's Business Daily
Alnylam Presents Detailed Results from the Positive HELIOS-B Phase 3 Study of Vutrisiran▼ in Patients with ATTR Amyloidosis with Cardiomyopathy at the European Society of Cardiology Congress
August 30, 2024
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam to Webcast Presentations at Upcoming September Investor Conferences
August 28, 2024
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
$100 Invested In This Stock 5 Years Ago Would Be Worth $300 Today
August 26, 2024
Via
Benzinga
How Is The Market Feeling About Alnylam Pharmaceuticals?
August 06, 2024
Via
Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
August 12, 2024
Via
Benzinga
Here's How Much You Would Have Made Owning Alnylam Pharmaceuticals Stock In The Last 10 Years
August 07, 2024
Via
Benzinga
The 3 Best Gene Editing Stocks to Buy in August 2024
August 07, 2024
Via
InvestorPlace
Alnylam to Present Detailed Results from the HELIOS-B Phase 3 Study of Vutrisiran▼ in Patients with ATTR Amyloidosis with Cardiomyopathy at the European Society of Cardiology Congress 2024
August 07, 2024
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
$100 Invested In This Stock 20 Years Ago Would Be Worth $4,100 Today
July 18, 2024
Via
Benzinga
Peering Into Alnylam Pharmaceuticals's Recent Short Interest
July 17, 2024
Via
Benzinga
Avadel Pharmaceuticals Stock Sees RS Rating Jump to 82
August 06, 2024
Via
Investor's Business Daily
DoorDash And Exact Sciences Are Among Top 10 Large Cap Gainers Last Week (July 28-Aug 3): Are The Others In Your Portfolio?
August 04, 2024
Via
Benzinga
Air Products Posts Upbeat Earnings, Joins Meta, Exact Sciences, Shake Shack, Clearwater Analytics And Other Big Stocks Moving Higher On Thursday
August 01, 2024
Via
Benzinga
Alnylam Pharmaceuticals Reports Second Quarter 2024 Financial Results and Highlights Recent Period Activity
August 01, 2024
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Ionis' Rare Development Disorder Drug Candidate 'Could Be Differentiated' From Peer Ultragenyx: Analyst
July 22, 2024
Via
Benzinga
Alnylam to Webcast Conference Call Discussing Second Quarter 2024 Financial Results
July 18, 2024
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam Stock Is a Blockbuster Biopharma In the Making
July 18, 2024
Via
InvestorPlace
35% Surge Just the Beginning? Alnylam’s Stock Poised for Massive Gains on Heart Drug Success.
July 11, 2024
Via
InvestorPlace
7 Cheap Biotech Stocks With Major Upside Potential
July 09, 2024
Via
InvestorPlace
Down 55%, Is Pfizer a Good Dividend Stock to Buy on the Dip?
July 08, 2024
Via
The Motley Fool
EXCLUSIVE: GLP-1 Weight-Loss Drugs Could Become A Trillion-Dollar Market, Predicts Tema ETFs CEO
July 07, 2024
Via
Benzinga
Topics
ETFs
$100 Invested In Alnylam Pharmaceuticals 10 Years Ago Would Be Worth This Much Today
July 03, 2024
Via
Benzinga
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.